Member Directory - Viral Hepatitis Working Group

Chair: David Thomas

Objectives:

  • Promote development of long-acting approaches to the treatment and/or prevention of hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. With HCV infection, the ultimate goal is a ‘test and cure’ approach to elimination.  With HBV infection, long-acting formulations to simplify treatment and prevention.
  • Bring clinical, public health, and regulatory expertise to solve this pharmacological challenge by identifying the optimal drug targets and encouraging their development in partnership with Pharma.  
  • Prioritize existing compounds with the pharmacologic and chemical properties that support long-acting formulation.

Interested in joining?

Please submit your request and your CV to Ana Cervantes. Acceptance requires a written nomination from a Hepatitis Working Group member and majority approval.

David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine.

Conflict of Interest: I am a member of a Data Monitoring Committee for Merck & Co.

Katia Boven, MD is a Vice President and the Global Head of Late Development for Infectious Diseases at Johnson and Johnson.

Conflict of interest: I own stock in Johnson and Johnson

Peggy is a Group Medical Director and Global Development lead for HCV products at AbbVie Inc.

Conflict of Interest: I own stock in both Merck and AbbVie.

Arnab is a founding PI at Calibr at Scripps Research and currently leads the chemistry group serving as Vice President of Medicinal Chemistry.

Conflict of Interest: I have no real or apparent conflicts of interest to report.
 

Dr. Cohen is Senior Vice President of the Hepatitis B Foundation, leading national and international efforts to eliminate hepatitis B through developing partnerships, capacity and strategies to improve hepatitis B and D screening, vaccination, and linkage to care.

Conflict of Interest: Dr. Cohen serves on community advisory boards for Gilead Sciences, Roche, Antios and GSK.
 

Dr. Feld attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology.

Conflicts of Interest: Dr. Jordan Feld received Personal fees for scientific consulting from: Abbott, Abbvie, Gilead, Enanta, Roche. Dr. Feld reports receiving grants for research from Abbvie, Gilead, Janssen, Wako/Fujifilm 

Oriel Fernandes is the Director of the Viral Hepatitis Program at the Clinton Health Access Initiative (CHAI) and is based in Kigali, Rwanda. CHAI is supporting countries in Asia and Sub-Saharan African to launch and expand access to hepatitis C and B testing and treatment programs and use market-shaping interventions to reduce commodity prices. 

Conflict of Interest: I have no real or apparent conflicts of interest to report.
 

Simon Fletcher is an Executive Director at Gilead Sciences, where he leads a group focused on developing novel therapies for HBV and other chronic viral infections. 

Conflict of interest: Dr Fletcher is an employee and stockholder of Gilead Sciences, Inc. 
 

Lobna Gaayeb manages the Long-Acting Technologies project at the Medicines Patent Pool. She has experience in coordinating international networks and scientific projects.

Conflict of Interest:  I have no real or apparent conflicts of interest to report.

Leah Johnson, PhD, is a Senior Research Chemist in the Center for Engineered Systems at RTI International.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Craig McClure iis a Senior Advisor to Infectious Disease Research and Labs (IDRL) at the Clinton Health Access Initiative (CHAI).

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. 

Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck; GSK; Janssen; ViiV Healthcare

Luisa Stamm, MD, PhD, is the Chief Medical Officer at Assembly Biosciences. 

Conflict of interest: Dr. Stamm is an employee and stock holder of Assembly Biosciences. 
 

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases Johns Hopkins Bayview Medical Center.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Dr. Norah Terrault is Professor of Medicine and Chief of Gastroenterology and Liver Diseases at the Keck School of Medicine at University of Southern California.

Conflict of Interest: Dr. Terrault has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Gilead, CCO Hepatitis, Allergan Pharmaceuticals, Dova Pharmaceuticals, Intercept, EXIGO Management Consultants, LLC, Genetech & Roche.